Zhao M, Abdel-Razek T, Sun M F, Gailani D
Departments of Pathology and Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA.
J Biol Chem. 1998 Nov 20;273(47):31153-9. doi: 10.1074/jbc.273.47.31153.
The glycosaminoglycan heparin enhances several reactions involving coagulation factor XI (FXI) including activation of FXI by factor XIIa, thrombin, and autoactivation; and inactivation of activated FXI (FXIa) by serine protease inhibitors. We examined the effect of heparin on inhibition of FXIa by the inhibitors C1-inhibitor (C1-INH) and antithrombin III (ATIII). Second order rate constants for inhibition in the absence of heparin were 1.57 x 10(3) and 0.91 x 10(3) M-1 s-1 for C1-INH and ATIII, respectively. Therapeutic heparin concentrations (0.1-1.0 units/ml) enhanced inhibition by ATIII 20-55-fold compared with 0.1-7.0-fold for C1-INH. For both inhibitors, the effect of heparin over a wide range of concentrations (10(-1) to 10(5) units/ml) produced bell-shaped curves, demonstrating that inhibition occurs by a template mechanism requiring both inhibitor and protease to bind to heparin. This implies that FXI/XIa contains structural elements that interact with heparin. Human FXI contains a sequence of amino acids (R250-I-K-K-S-K) in the apple 3 domain of the heavy chain that binds heparin (Ho, D., Badellino, K., Baglia, F., and Walsh, P. (1998) J. Biol. Chem. 273, 16382-16390). To determine the importance of this sequence to heparin-mediated reactions, recombinant FXI molecules with alanine substitutions for basic amino acids were expressed in 293 fibroblasts, and tested in heparin-dependent assays. Inhibition of FXIa by ATIII in the presence of heparin was decreased 4-fold by alanine substitution at Lys253 (A253), with smaller effects noted for mutants A255 and A252. FXI undergoes autoactivation to FXIa in the presence of heparin. The rate of autoactivation was decreased substantially for A253 with modest decreases for A255 and A252. Substituting all four charged residues in the sequence resulted in a profound decrease in autoactivation, significantly greater than for any single substitution. Relative affinity for heparin was tested by determining the concentration of NaCl required to elute FXIa from heparin-Sepharose. Wild type FXIa eluted from the column at 320 mM NaCl, whereas FXIa with multiple substitutions (A252-254 or A250-255) eluted at 230 mM NaCl. All proteins with single substitutions in charged amino acids eluted at intermediate NaCl concentrations. The data indicate that FXI/XIa must bind to heparin for optimal inhibition by ATIII and for autoactivation. Lys253 is the most important amino acid involved in binding, and Lys255 and Lys252 also have roles in interactions with heparin.
糖胺聚糖肝素可增强涉及凝血因子XI(FXI)的多种反应,包括因子XIIa、凝血酶对FXI的激活以及FXI的自身激活;还可增强丝氨酸蛋白酶抑制剂对活化FXI(FXIa)的灭活作用。我们研究了肝素对抑制剂C1抑制剂(C1-INH)和抗凝血酶III(ATIII)抑制FXIa的影响。在不存在肝素的情况下,C1-INH和ATIII抑制反应的二级速率常数分别为1.57×10³和0.91×10³ M⁻¹ s⁻¹。治疗浓度的肝素(0.1 - 1.0单位/毫升)使ATIII的抑制作用增强了20 - 55倍,而使C1-INH的抑制作用增强了0.1 - 7.0倍。对于这两种抑制剂,在很宽的肝素浓度范围(10⁻¹至10⁵单位/毫升)内,肝素的作用产生钟形曲线,表明抑制作用通过一种模板机制发生,该机制要求抑制剂和蛋白酶都与肝素结合。这意味着FXI/XIa含有与肝素相互作用的结构元件。人FXI在重链的苹果3结构域中含有一段与肝素结合的氨基酸序列(R250 - I - K - K - S - K)(Ho, D., Badellino, K., Baglia, F., and Walsh, P. (1998) J. Biol. Chem. 273, 16382 - 16390)。为了确定该序列对肝素介导反应的重要性,在293成纤维细胞中表达了用丙氨酸替代碱性氨基酸的重组FXI分子,并在依赖肝素的试验中进行测试。在肝素存在的情况下,Lys253位点的丙氨酸替代(A253)使ATIII对FXIa的抑制作用降低了4倍,A255和A252突变体的影响较小。在肝素存在的情况下,FXI会自身激活为FXIa。A253的自身激活速率大幅降低,A255和A252则有适度降低。将该序列中的所有四个带电荷残基进行替代导致自身激活显著降低,明显大于任何单个替代的情况。通过测定从肝素 - 琼脂糖凝胶上洗脱FXIa所需的NaCl浓度来测试对肝素的相对亲和力。野生型FXIa在320 mM NaCl时从柱上洗脱,而具有多个替代(A252 - 254或A250 - 255)的FXIa在230 mM NaCl时洗脱。所有在带电荷氨基酸处有单个替代突变的蛋白质在中间NaCl浓度时洗脱。数据表明,FXI/XIa必须与肝素结合才能实现ATIII的最佳抑制作用以及自身激活。Lys253是参与结合的最重要氨基酸,Lys255和Lys252在与肝素的相互作用中也起作用。